In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

(2022) James A. Dowell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical exposure–response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model

(2021) Maxwell J. Lasko et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria

(2020) Kamilia Abdelraouf et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans

(2019) Jürgen B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

(2019) Jodie C. Hamrick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods

(2019) Tomefa E Asempa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria

(2018) James M. Kidd et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

(2018) Zheng Pang et al.   BIOTECHNOLOGY ADVANCES

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates

(2011) Rebecca A. Keel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY